First Author: S.Ch'ng UK
Co Author(s): S.S. Deol P. Tesha 0 0 0 0 0 0 0 0 0
Back to previous
To evaluate 1 year outcomes for neovascular age-related macular degeneration treated using a 'Don't Treat and Extend' dosing regimen with ranibizumab.
Lincoln County Hospital, Lincolnshire, UK
Retrospective study of 90 eyes of 85 patients with nAMD treated with intravitreal ranibizumab with 1 year follow up. All patients recieved initial three monthly injections. Follow up was extended by 2 weeks per visit depending on results of optical coherence tomogprahy and clinical findings. Maximum follow-up was 12 weeks.
8.8 letters average improvement (comparable to 11.3 ANCHOR, 7.2 MARINA, and 9.3 PrONTO). Average number of treatments was 5.3, compared to 5.6 in PrONTO.
'Dont Treat and Extend' dosing regimen delivers good visual outcomes comparable to published data. This regimen may allow patients undergoing nAMD to be followed up less frequently.